Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low-density lipoprotein receptor class A domain containing 4 (LDLRAD4)
- Target
- LDLRAD4
- Molecular classification
- Receptor, Low-density lipoprotein receptor family, Single-pass membrane protein
01
Overview
Low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) is a single-pass membrane receptor in the LDLR family, characterized by the presence of a class A domain that mediates ligand binding. LDLRAD4 mainly acts as a negative regulator of the TGF-beta signaling pathway, thus impacting key cellular processes such as proliferation, migration, apoptosis, and extracellular matrix production. It is expressed in various tissues, with upregulation documented in liver cancer cells where it promotes tumorigenesis. Its molecular interactions include binding to R-SMAD proteins and the E3 ubiquitin ligase Nedd4. Pathogenic mutations or dysregulation in LDLRAD4 can contribute to cancer and rare developmental disorders. Elevated expression or functional alteration may serve as a biomarker or therapeutic target in oncology and other diseases.
- Other names
- LRAD4LDLC48230401C20RikA430108L08RikD18Ertd653eD330030L18Rik
02
Mechanism of action
Inhibits TGF-beta signaling by binding SMAD2/3 and competing with canonical pathway components, thereby modulating cell growth, differentiation, and apoptosis
03
Biological functions
Signal transductionNegative regulation of TGF-beta signalingCell proliferationCell differentiationApoptosisCell motilityExtracellular matrix productionImmunosuppressionNegative regulation of cell migration
04
Disease associations
Cancer (especially hepatic/liver cancer)Geleophysic dysplasia 1 (rare developmental disorder)Potential contributor to psychiatric disorders
05
Safety considerations
Therapeutic targeting may impact TGF-beta pathway, which is important for tissue homeostasis, immune regulation, and has pleiotropic effects; off-target effects may include altered cell proliferation, differentiation, and immune function
06
Biomarkers
Elevated LDLRAD4 expression in hepatic cancer cells may serve as a biomarker for cancer proliferation and migration
Beyond the preview
Go deeper on Low-density lipoprotein receptor class A domain containing 4 (LDLRAD4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Low-density lipoprotein receptor class A domain containing 4 (LDLRAD4).